Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03256045 · BASELINE

Baseline characteristics

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma · Source last updated 2022-05-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      9
    units
    Participants
groups
  1. description
    Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          49
          upper Limit
          72
          value
          67
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Customized
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      Male
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Female
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          8
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Ethnicity (NIH/OMB)
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        title
        American Indian or Alaska Native
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Asian
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Native Hawaiian or Other Pacific Islander
      4. measurements
        1. group Id
          BG000
          value
          0
        title
        Black or African American
      5. measurements
        1. group Id
          BG000
          value
          9
        title
        White
      6. measurements
        1. group Id
          BG000
          value
          0
        title
        More than one race
      7. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race (NIH/OMB)
    unit Of Measure
    Participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          2
          upper Limit
          9
          value
          5
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Prior therapy regimes
    unit Of Measure
    number of regimens
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          88.9
    param Type
    NUMBER
    title
    Prior autologous transplant
    unit Of Measure
    percentage of participants
  7. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          1
          upper Limit
          3
          value
          2.5
    description
    Revised ISS is the Revised International Staging System, which is used to stage multiple myeloma at diagnosis. It takes into account a patient's albumin, beta-2-microglobulin, lactate dehydrogenase levels, and chromosomal abnormalities detected by FISH to predict survival. There are three stages: I, II, and III. The lower the stage, the longer the progression-free survival.
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Revised ISS Stage
    unit Of Measure
    ISS Stage
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      9
    units
    Participants
groups
  1. description
    Patients undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay. Regardless of assay results, patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19, and carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Chemo Assay and Treatment With Panobinostat, Carfilzomib, and Dexamethasone
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          49
          upper Limit
          72
          value
          67
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Customized
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          6
      title
      Male
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Female
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
        title
        Hispanic or Latino
      2. measurements
        1. group Id
          BG000
          value
          8
        title
        Not Hispanic or Latino
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Ethnicity (NIH/OMB)
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          0
        title
        American Indian or Alaska Native
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Asian
      3. measurements
        1. group Id
          BG000
          value
          0
        title
        Native Hawaiian or Other Pacific Islander
      4. measurements
        1. group Id
          BG000
          value
          0
        title
        Black or African American
      5. measurements
        1. group Id
          BG000
          value
          9
        title
        White
      6. measurements
        1. group Id
          BG000
          value
          0
        title
        More than one race
      7. measurements
        1. group Id
          BG000
          value
          0
        title
        Unknown or Not Reported
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race (NIH/OMB)
    unit Of Measure
    Participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          2
          upper Limit
          9
          value
          5
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Prior therapy regimes
    unit Of Measure
    number of regimens
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          88.9
    param Type
    NUMBER
    title
    Prior autologous transplant
    unit Of Measure
    percentage of participants
  7. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          1
          upper Limit
          3
          value
          2.5
    description
    Revised ISS is the Revised International Staging System, which is used to stage multiple myeloma at diagnosis. It takes into account a patient's albumin, beta-2-microglobulin, lactate dehydrogenase levels, and chromosomal abnormalities detected by FISH to predict survival. There are three stages: I, II, and III. The lower the stage, the longer the progression-free survival.
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Revised ISS Stage
    unit Of Measure
    ISS Stage

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice